Shares of genomics company Illumina (NASDAQ:ILMN) jumped 3.7% in the pre-market session after analysts at Robert W. Baird increased their price target on the life sciences company's stock to $105.00.

Genomics company Illumina (NASDAQ:ILMN) will be reporting earnings this Thursday afternoon. Here’s what to expect.

Illumina (NASDAQ:ILMN) stock dips as Scotiabank downgrades. However, peers Danaher (DHR) stock and Thermo Fisher (TMO) stock win upgrades. Read more here.

Shares of genomics company Illumina (NASDAQ:ILMN) fell 4.2% in the morning session after a Citi analyst downgraded the stock to 'Sell' from 'Neutral' and lowered the price target.

In a report released today, Daniel Brennan from TD Cowen maintained a Hold rating on Illumina, with a price target of $106.00. The company’s shares closed today at $96.94. Eleva ...

Bausch Health will acquire DURECT and larsucosterol, aiming for FDA approval of a first treatment for alcoholic hepatitis via ...

The market expects Illumina (ILMN) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is ...

Analysts have given IQVIA Hldgs a total of 7 ratings, with the consensus rating being Neutral. The average one-year price target is $174.0, indicating a potential 8.32% upside.

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Illumina (ILMN). But which of these two ...

Illumina has an analyst consensus of Moderate Buy, with a price target consensus of $107.73, which is a 10.6% upside from current levels. In a report issued on June 24, Barclays also maintained a Sell ...

Now that PacBio has broken through the $1 level that avoids Nasdaq delisting for now, we can focus on what might be ahead: ...